Designing Longevity
Skip to main content

Digestive Peptide Evidence

Peptide medicines such as linaclotide, plecanatide and teduglutide each have specific labeled uses. Experimental claims need evidence for the exact compound, the condition studied and an outcome that matters to patients.

Sources reviewed November 13, 2026 · How we work

Linaclotide and plecanatide for specific constipation diagnoses

Linzess and Trulance activate the same intestinal receptor, guanylate cyclase-C, to increase fluid secretion. Labels cover adult IBS-C and adult chronic idiopathic constipation. Linzess also has separately scoped pediatric indications. The studies measured outcomes for each specific diagnosis.

Sources for this section

Teduglutide and octreotide in specialist care

Gattex (teduglutide) addresses short bowel syndrome in people ages 1 and older who depend on parenteral support. Studies tracked whether patients could reduce the volume of IV nutrition or fluids.

Sandostatin Injection (octreotide acetate) has labeled uses for severe diarrhea and flushing associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors. These are specific tumor-related conditions with their own specialist care.

Sources for this section

KPV and BPC-157 digestive research

Researchers observed changes in inflammation with KPV in intestinal cells and mouse colitis models. FDA identified no human exposure data for drug products containing KPV in its review. Human benefit and safety for digestive disease remain undetermined.

Research on BPC-157 includes animal models of injury and repair. Human outcomes for common digestive symptoms or inflammatory bowel disease remain unestablished. FDA’s review highlights gaps in safety information and concerns about how well compounded peptide products can be characterized.

Sources for this section

Larazotide in celiac disease research

Larazotide acetate is a peptide studied in adults with celiac disease who continued to have symptoms while following a gluten-free diet. The phase 3 trial stopped after an interim analysis failed to support continuing. This research addressed a defined celiac population, and clinical effectiveness remains unestablished.

Sources for this section
Explore Gut Health & Digestion